Skip to content

Study · Not a test of the peptide alone · 1997

3 results

Effects of muscarinic and adrenergic blockade on growth hormone secretion induced by growth hormone-releasing peptide-2 (GHRP-2) in ovariectomized ewes.

Roh SG, Hirota M, He ML, Matsunaga N, Hidaka S, Hidari H

Endocrine journal1 Dec 1997Cited by 2 (Europe PMC)

PMID9622303 (opens in a new tab)DOI10.1507/endocrj.44.861 (opens in a new tab)PepBankPUB-09622303
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01AnimalNot a test of GHRP-2 aloneAnimal study (in vivo)Mechanism

    In ovariectomized ewes, the muscarinic antagonist atropine blunted the GH secretion caused by GHRP‑2.

    In plain wordsIn ewes, atropine, which blocks muscarinic receptors, weakened the growth hormone release caused by GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    DecreaseGH secretion after atropine
    Study

    sheep (ovariectomized ewes)n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Cholinergic muscarinic antagonist, atropine (0.2 mg/kg, i.v., 15 min before GHRP-2 administration) blunted the GH secretion caused by GHRP-2 (12.5 microg/kgBW)
    1 context sentence
    Summary · context
    This study was performed to investigate whether the blockade of cholinergic muscarinic and adrenergic pathways was involved in the GH-releasing effect of GH-releasing peptide-2 (GHRP-2) in ovariectomized ewes.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 02AnimalNot a test of GHRP-2 aloneAnimal study (in vivo)Mechanism

    In ovariectomized ewes, the alpha-adrenergic antagonist phentolamine did not affect the GH response to GHRP‑2.

    In plain wordsIn ewes, phentolamine, which blocks alpha-adrenergic receptors, did not change the growth hormone response to GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH response after phentolamine
    Study

    sheep (ovariectomized ewes)n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    alpha-Adrenergic antagonist phentolamine (15 microg/kgBW x min, infusion from -15 to 30 min) did not affect the GH response to GHRP-2
    1 context sentence
    Summary · context
    This study was performed to investigate whether the blockade of cholinergic muscarinic and adrenergic pathways was involved in the GH-releasing effect of GH-releasing peptide-2 (GHRP-2) in ovariectomized ewes.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 03AnimalNot a test of GHRP-2 aloneAnimal study (in vivo)Mechanism

    In ovariectomized ewes, the beta-adrenergic antagonist propranolol did not suppress GHRP‑2-induced GH release.

    In plain wordsIn ewes, propranolol, which blocks beta-adrenergic receptors, did not reduce the growth hormone release caused by GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH release after propranolol
    Study

    sheep (ovariectomized ewes)n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    beta-adrenergic antagonist propranolol (0.25 mg/kgBW, i.v., 15 min before GHRP-2 administration) did not suppress the GHRP-2-induced GH release.
    1 context sentence
    Summary · context
    This study was performed to investigate whether the blockade of cholinergic muscarinic and adrenergic pathways was involved in the GH-releasing effect of GH-releasing peptide-2 (GHRP-2) in ovariectomized ewes.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.